Current treatments of metastatic renal cell carcinoma
| dc.contributor.advisor | Juhász, Balázs | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Onkológiai Intézet::Onkológiai Tanszék | hu_HU |
| dc.contributor.author | Lule, Andrew Kaleebu | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Kiss, Zoltán | |
| dc.contributor.opponent | Szekanecz, Éva | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Urológiai Klinika | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Onkológiai Intézet::Onkológiai Tanszék | hu_HU |
| dc.date.accessioned | 2020-02-24T10:38:27Z | |
| dc.date.available | 2020-02-24T10:38:27Z | |
| dc.date.created | 2019-06-06 | |
| dc.description.abstract | Renal cell carcinoma is the most common malignant tumour of the kidney approximately 85-90%.It accounts for about 2-3% of all cancers in adults. Metastatic renal cell carcinoma is treated with immune therapy and targeted therapy.Patients are grouped into good, intermediate and poor risk groups and treatment provided accordingly.There is first,second and third lines of treatment for each group.Treatment isn't curable but palliative. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 37 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/281199 | |
| dc.language.iso | en | hu_HU |
| dc.subject | cytokines immune therapy | hu_HU |
| dc.subject | targeted therapy | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Current treatments of metastatic renal cell carcinoma | hu_HU |